Home > Oncology > SABCS 2021 > Phase 1–3 Trials > Efficacy of pyrotinib plus capecitabine confirmed in previously treated patients

Efficacy of pyrotinib plus capecitabine confirmed in previously treated patients

Presented By
Prof. Binghe Xu, Chinese Academy of Medical Sciences, China
Conference
SABCS 2021
Trial
Phase 3, PHOEBE
Patients with previously treated HER2-positive metastatic breast cancer who received pyrotinib plus capecitabine had longer overall survival than patients who received lapatinib plus capecitabine, according to updated results from the phase 3 PHOEBE trial. Patients with metastatic HER2-positive breast cancer are typically treated with the HER2-targeted therapies trastuzumab and pertuzumab in combination with a taxane, but resistance to this regimen inevitably develops. Patients who progress on this standard therapy may then be treated with lapatinib plus capecitabine or with alternative HER2-targeted therapies, such as trastuzumab plus emtansine. Pyrotinib is an irreversible tyrosine kinase receptor inhibitor that targets HER2, as well as the related proteins HER4 and HER1. A prior phase 2 clinical trial found that pyrotinib plus capecitabine led to clinical responses in previously treated patients with HER2-positive metastatic breast cancer [1]...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on